-
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG) Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-15 Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, Sema Sezgin Goksu, Irem Bilgetekin, Burcu Cakar, Abdullah Sakin, Ozturk Ates, Tugba Basoğlu, Cagatay Arslan, Atike Gokcen Demiray, Semra Paydas, Irfan Cicin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Hakan Kosku, Aytuğ Uner, Perran Fulden Yumuk, Gungor Utkan, Umut Kefeli, Ozgur Tanriverdi, Havva Cınkır, Ozge Gumusay, Nazım Serdal Turhal, Serkan Menekse
Adrenocortical carcinoma (ACC) is a rare yet highly malignant tumor associated with significant morbidity and mortality. This study aims to delineate the clinical features, survival patterns, and treatment modalities of ACC, providing insights into the disease's prognosis. A retrospective analysis of 157 ACC patients was performed to assess treatment methodologies, demographic patterns, pathological
-
An Update on the Role of mpMRI and 68Ga-PSMA PET Imaging in Primary and Recurrent Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-13 Hamed Bagheri, Seyed Rabi Mahdavi, Parham Geramifar, Ali Neshaseh-Riz, Masoumeh Sajadi Rad, Habibollah Dadgar, Hossein Arabi, Habib Zaidi
The objective of this work was to review comparisons of the efficacy of Ga-PSMA-11 (prostate-specific membrane antigen) PET/CT and multiparametric magnetic resonance imaging (mpMRI) in the detection of prostate cancer among patients undergoing initial staging prior to radical prostatectomy or experiencing recurrent prostate cancer, based on histopathological data. A comprehensive search was conducted
-
A Randomized, double-blind, placebo-controlled trial evaluating the effect of topical urea for secondary prophylaxis of hand foot skin reaction in renal cell cancer patients on sunitinib therapy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-13 Syed Shariq Naeem, Pooja Gupta, Ranjit Kumar Sahoo, VL Kumar, T Velpandian, Archana Singh, Atul Batra, Raja Pramanik, Sameer Rastogi, Saumya Srivastava
Hand foot skin reaction (HFSR) is a common dose-limiting adverse effect of multi kinase inhibitors (MKI) whose mechanism is not fully understood, and the prophylaxis is inadequate. In this pilot study, a double-blind, randomized placebo-controlled trial was conducted to evaluate the effect of topical urea in secondary prevention of sunitinib-induced HFSR in renal cell cancer patients. Out of 55 screened
-
NLR outperforms low haemoglobin and high platelet count as predictive and prognostic biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Matthew Young, Jose C. Tapia, Bernadett Szabados, Agne Jovaisaite, Francesca Jackson-Spence, Elizabeth Nally, Thomas Powles
Reliable biomarkers in renal cell carcinoma (RCC) remain elusive. While several markers have been shown to be associated with prognosis, and may aid in risk assessment, predictive biomarkers of response to immune checkpoint inhibitors (ICIs) have not been established. Previous studies have shown that a high pre-treatment neutrophil-lymphocyte ratio (NLR) is a negative prognostic factor in RCC. However
-
Risk-adapted strategy combining magnetic resonance imaging and prostate-specific antigen density to individualize biopsy decision in patients with PI-RADS 3 'gray zone' lesions Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Cagri Akpinar, Digdem Kuru Oz, Alkan Oktar, Evren Suer, Eriz Ozden, Nuray Haliloglu, Omer Gulpinar, Mehmet Ilker Gokce, Cagatay Gogus, Sumer Baltaci
Recent guidelines suggest that biopsy may be omitted in some groups of patients with PI-RADS 3 lesions on mpMRI. In this study, we aimed to evaluate biopsy strategies involving prostate-specific antigen density (PSAd) to avoid unnecessary biopsy versus the risk of missing clinically significant prostate cancer (csPCa) in patients with PI-RADS 3 lesions. Data of 616 consecutive patients who underwent
-
Cardiovascular Toxicity Associated with Androgen Receptor Axis-Targeted Agents in Patients with Prostate Cancer: A Meta-analysis of Randomized Controlled Trials Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Susu Zhou, Parissa Alerasool, Noriko Kishi, Himanshu Joshi, Gagan Sahni, Che-Kai Tsao
Second-generation androgen receptor axis-targeting (ARAT) agents have become a standard treatment for patients with advanced prostate cancer (PC), however much remains unknown about the potential cardiovascular toxicities. We performed a systematic search of PubMed, Embase, Web of Science, and Cochrane library for randomized controlled trials of patients receiving ARAT agents for PC from inception
-
Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Jakob N. Henriksen, Charlotte U. Andersen, Niels Fristrup
Inter-individual variability in drug response pose significant challenges to treatment with tyrosine kinase inhibitors (TKI) in patients with metastatic renal cell carcinoma (mRCC). TKIs meet traditional criteria for using therapeutic drug monitoring (TDM), but research is still limited. Understanding the role of TDM in individualizing treatment strategies could help optimize treatment. Here we review
-
Development of a nomogram model to identify appropriate candidates from cytoreductive nephrectomy in metastatic renal cell carcinoma based on the Surveillance, Epidemiology and End Results database Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-06 Kong Ren, Hao Ning, Hai-hu Wu, Fei Wu, Jia-ju Lyu
This study sought to assess the prognostic enhancement associated with cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) and to establish a predictive nomogram for identifying patients who would most likely benefit from CN. Although a survival benefit was observed in patients with metastatic renal cell carcinoma (mRCC) who underwent cytoreductive nephrectomy (CN), there is a
-
Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-05 Robert H. Mbilinyi, Pavlos Msaouel, Priya Rao, Jose A. Karam, Nizar M. Tannir, Chad Tang
Renal medullary carcinoma (RMC) is a rare and aggressive cancer that occurs in young individuals of African descent with sickle cell trait. Unlike renal cell carcinoma with a five-year overall survival rate of up to 77%, fewer than 5% of patients with RMC survive beyond 3 years with standard systemic therapies. RMC responds poorly to treatments effective for other renal malignancies. This highlights
-
Effectiveness of Adjuvant Chemotherapy in Variant Histology Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Stabilized Inverse Probability Treatment Weighting Analysis of Single Center Experience Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-04 Inkeun Park, Jungyo Suh, Bumjin Lim, Cheryn Song, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Yong Mee Cho, Jaelyun Lee, Bumsik Hong
The study aimed to investigate the impact of adjuvant chemotherapy on time to recurrence (TTR) and overall survival (OS) in patients with histologic variants of upper tract urothelial carcinoma (VUTUC) following radical nephroureterectomy (RNU). A retrospective review of 131 VUTUC patients' medical records, from a pool of 368 non-metastatic localized or locally advanced UTUC cases, treated at a single
-
IMPROVER (Involving Men with Prostate Cancer in Engaged Research): Assessing Patient Experience With Testing, Diagnosis, And Surveillance Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-04 Marc Walsh, Asia Jordan, Lea Schäfer, Jana Joha, Ben Heapes, Megan Noonan, William Gallagher, Hubert Gallagher, Rustom P. Manecksha, David Galvin, Greg Nason, Terri Martin, Ciara Lyons, Robert O'Connor, Frances J. Drummond, Claire Kilty, Antoinette S. Perry, UCD Prostate Patient Advisory Committee
We collaborated with patients and healthcare professionals through focus groups and an online questionnaire, to learn about their experience and needs in the detection, diagnosis and surveillance of prostate cancer. We identified a need for clear and understandable written information to be given to people at the start of their journey. Whilst patients are generally satisfied with the different tests
-
Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-02 Zuzana Orszaghova, Dominika Galikova, Peter Lesko, Jana Obertova, Katarina Rejlekova, Zuzana Sycova-Mila, Patrik Palacka, Katarina Kalavska, Daniela Svetlovska, Beata Mladosievicova, Jozef Mardiak, Michal Mego, Michal Chovanec
We evaluated chemotherapy-induced peripheral neuropathy (CIPN) after curative treatment for testicular germ cell tumors (GCT) and its association with quality of life (QOL) in the 151 cancer survivors. Survivors with high CIPN scores reported impaired QOL, worse functional and symptom scales. CIPN is a strong predictor of impairment in QOL among GCT survivors. Physicians should never overtreat patients
-
A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non–Muscle-Invasive Bladder Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-29 Dengxiong Li, Ruicheng Wu, Jie Wang, Junjiang Ye, Qingxin Yu, Dechao Feng, Ping Han
There is an urgent need to identify a robust predictor for BCG response in patients with non–muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy. After acquiring the ethics approval, we searched the electric medical records in
-
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-28 Jazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, Ahmed El-Zawahry, James Peabody, Tiffany Pearce, Nicole Adams, Mustafa Deebajah, Danuta Dynda, Kara Babaian, Jane Crabtree, Kristin Delfino, Kevin McVary, Kathy Robinson, Krishna Rao, Shaheen Alanee
To report urinary bother, urinalysis changes, disease-free survival (DFS), and overall survival (OS) over 2 years for subjects enrolled in a phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette-Guérin (BCG) in combination with systemic pembrolizumab for recurrent or persistent high-grade non-muscle invasive bladder cancer (HGNMIBC). Eighteen patients consented to the study
-
Telemedicine for Multidisciplinary Urologic Cancer Care: A Prospective Single Institution Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-24 Frederick Okoye, Adam J. Gadzinski, Rishi Sekar, Isabelle Abarro, Petros Grivas, Scott Tykodi, Jay Liao, Jonathan Chen, Jing Zeng, Jonathan Wright, John L. Gore
We rapidly implemented a telemedicine Multidisciplinary Urologic Cancer Clinic (MDUCC) at the University of Washington/Seattle Cancer Care Alliance during the peak of the COVID-19 Public Health Emergency to maintain our ability to provide multidisciplinary cancer care. We report our experiences though assessment of patient-reported outcomes from our telemedicine MDUCC. Video visits with a urologic
-
Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis) Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-23 Jeffrey Graham, Sunita Ghosh, Rodney H. Breau, Lori Wood, Simon Tanguay, Dominick Bosse, Aly-Khan Lalani, Bimal Bhindi, Daniel Heng, Antonio Finelli, Nazanin Fallah-Rad, Vincent Castonguay, Naveen S. Basappa, Denis Soulières, Frédéric Pouliot, Christian Kollmannsberger, Georg A. Bjarnason
Cabozantinib, an oral multi-targeted tyrosine kinase inhibitor (TKI), has demonstrated efficacy in metastatic renal cell carcinoma (mRCC). The association between toxicity and therapeutic effectiveness has been established with other TKIs. We investigated whether cabozantinib dose reductions, a surrogate for toxicity and adequate drug exposure, were associated with improved clinical outcomes in mRCC
-
Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-17 Kassandra Dindinger-Hill, Siqi Hu, Atticus Hickman, Mouneeb Choudry, Jeffrey Vehawn, John Snyder, Vikrant Deshmukh, Michael Newman, Ankita Date, Carlos Galvao, Manish Kohli, Brock O'Neil, Bogdana Schmidt, Christopher Dechet, Mia Hashibe, Alejandro Sanchez
Obesity in prostate cancer survivors may increase mortality. Better characterization of this effect may allow better counseling on obesity as a targetable lifestyle factor to reduce mortality in prostate cancer survivors. The purpose of this study was to determine whether pre- and post-diagnostic obesity and weight change affect all-cause mortality, cardiovascular disease specific mortality, and prostate
-
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-16 Edouard H. Nicaise, Benjamin N. Schmeusser, Adil Ali, Eric Midenberg, Arnold R. Palacios, Blaise Hartsoe, Ethan Kearns, Sriram Ambadi, Dattatraya H. Patil, Shreyas S. Joshi, Vikram M. Narayan, Sarah P. Psutka, Bassel Nazha, Jacqueline T. Brown, Kenneth Ogan, Mehmet A. Bilen, Viraj A. Master
Baseline sarcopenia and postoperative changes in muscle mass are independently associated with overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN). Here we examine the relationships between preoperative (baseline), postoperative changes in muscle quantity, and survival outcomes following CN as determined by linear segmentation, a clinic-friendly
-
Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-15 Sarah Fleming, Dina Gifkins, Helaine E. Resnick, Waleed Shalaby, Philip Rosenberg, Chris Gaj, Vittorio Maio, Albert Crawford, Grace Lu-Yao, Jianjun Gao, Arlene Siefker-Radtke
To understand the impact of genetic alterations on disease progression in metastatic urothelial carcinoma, physician-provided clinical data from 414 patients was assessed. In patients treated with first-line immune checkpoint inhibitors only, those with alterations had significantly higher rates of progression than patients with wild-type . Understanding the impact of alterations on disease progression
-
The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-15 Margaret Meagher, Kylie M. Morgan, Leah Deshler, Dhruv Puri, Kit Yuen, Aditya Bagrodia, Brent Rose, Tyler Stewart, Amirali Salmasi
The role of local definitive therapy in addition to systemic treatment in clinically positive regional lymph node (cN+) bladder cancer is yet to be determined. Herein, we sought to investigate the role of radical cystectomy (RC) in management of patients with cN+ bladder cancer at US Veterans Health Administration Facilities. We identified patients diagnosed with cN+ bladder cancer between 2000-2017
-
Aquired cystic disease – associated renal cell carcinoma: a systematic review and meta-analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-14 Nguyen Xuong DUONG, Minh-Khang LE, Tuan Thanh NGUYEN, Duy Duc NGUYEN, Huy Gia Vuong, Tetsuo KONDO, Takahiko MITSUI
Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web
-
Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-12 Xin Wang, Larissa Waldman, Yael Silberman, Michael Wang, Caleb Tackey, Lilian Hanna, Danny Vesprini, Urban Emmenegger, Andrea Eisen, Martin Smoragiewicz
An estimated 20% to 30% of men with advanced prostate cancer carry a mutation in DNA damage repair genes, of which half are estimated to be germline. Eligibility criteria for germline genetic testing expanded significantly for Ontario patients in May 2021 and many centers adopted a “mainstream” model, defined as oncologist-initiated genetic testing. We conducted a retrospective chart review to report
-
Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-09 Shugo Yajima, Yasukazu Nakanishi, Ryo Andy Ogasawara, Naoki Imasato, Kohei Hirose, Sao Katsumura, Madoka Kataoka, Hitoshi Masuda
Sarcopenia is a condition of low muscle strength and quantity, severe if low physical performances. The sarcopenia index (SI), calculated by blood levels of creatinine and cystatin C, had been reported to be correlated with skeletal muscle mass and is a potential simple screening tool for sarcopenia. We hypothesized that patients with a low SI, meaning low muscle mass, would have an inflated estimated
-
Clinical Profile and Outcomes of Carcinoma Penis Patients Receiving Systemic Therapy at an Indian tertiary care Center: A Retrospective Observational Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-07 Vanita Noronha, Venkatesh Kapu, Amit Joshi, Nandini Menon, Ajaykumar Singh, Gagan Prakash, Santosh Menon, Nilesh Sable, Vedang Murthy, Mahendra Pal, Amandeep Arora, Sravan Kumar, Shripad Banavali, Kumar Prabhash
Penile carcinoma is rare and data are scarce. Observational study at Tata Hospital (Mumbai) on 91 patients. In 19 patients treated with neoadjuvant paclitaxel + platinum, ORR=37%, surgical resection rate=31.5%. Med OS in 71 patients treated with curative intent was 33.8 months. In 20 patients treated with palliative chemotherapy, ORR-20%, mediatn OS=11.4 months
-
The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-06 Luna van den Brink, Annebeth E. C. Ruiter, Brunolf W. Lagerveld, Niels M. Graafland, Axel Bex, Harrie P. Beerlage, Jeroen R. A. van Moorselaar, Patricia J. Zondervan
To describe the impact of a multidisciplinary tumor board (MTB) for renal cell carcinoma (RCC) patients in a locoregional renal cancer network by evaluating shared decision making (SDM) and adherence to MTB recommendations. This prospective cohort study included all cases from a Dutch renal cancer network with suspicion of or histologically confirmed RCC discussed in MTBs between 2017-2022. Main endpoints
-
Ejaculation Frequency and Prostate Cancer Risk: A Narrative Review of Current Evidence Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Emmanuel Kokori, Gbolahan Olatunji, David Timilehin Isarinade, John Ehi Aboje, Ikponmwosa Jude Ogieuhi, Zainab Doyinsola Lawal, Nathnael Abera Woldehana, Muhammad Wajeeh Nazar, Godfred Yawson Scott, Nicholas Aderinto
Prostate cancer, constituting a substantial portion of global cancer incidence and mortality, prompts a critical examination of potential modifiers, notably ejaculation frequency. This narrative review explores the complex relationship between ejaculation frequency and prostate cancer risk, addressing the paucity of consensus and the intricate interplay of factors. The evidence drawn from eleven studies
-
Recurrent bacteriuria as a prognosis marker in the adjuvant treatment of non-muscle invasive bladder cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Juliusz J. Szczesniewski, Magaly T. Márquez-Sánchez, Bárbara Padilla-Fernández, Luis Llanes-González, María F. Lorenzo-Gómez
Purpose : Bacteriuria may affect the response to adjuvant therapy in non-muscle invasive bladder cancer (NMIBC). The main aim of this study was to examine the effect of recurrent bacteriuria (RB) on the prognosis of NMIBC in women receiving intravesical therapy. Materials and methods : We designed a prospective observational study from 2012 to 2019. We included women with bladder cancer treated with
-
Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021. Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-02 Jose C. Tapia, Freya Bosma, Javier Gavira, Sofia Sanchez, Maria Alejandra Molina, Judit Sanz-Beltran, Cristina Martin-Lorente, Georgia Anguera, Pablo Maroto
Metastatic urothelial carcinoma (mUC) is a lethal disease with limited treatment options. We aimed to compare the treatment patterns and outcomes of patients with mUC who were treated before and after the introduction of immune checkpoint inhibitors (ICIs) at a tertiary hospital in Barcelona. Single-centre retrospective study from 2004 to 2021. Access to ICIs began in December 2014. We analysed differences
-
Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Carolin Siech, Simone Morra, Lukas Scheipner, Andrea Baudo, Letizia M.I. Jannello, Mario de Angelis, Jordan A. Goyal, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Nicola Longo, Luca Carmignani, Ottavio de Cobelli, Sascha Ahyai, Alberto Briganti, Philipp Mandel, Luis A. Kluth, Felix K.H. Chun, Pierre I. Karakiewicz
In stage-specific analyses of 98,142 renal cell carcinoma patients, married status independently predicted higher nephrectomy rates in males and females. In stage IV, married status predicted higher systemic therapy rate in males, but not in females. Married males exhibited lower cancer specific mortality across all stages; married females only in stages I and III (all ≤ .02).
-
Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Tenaw Tiruye, Michael O'Callaghan, Liesel M. FitzGerald, Kim Moretti, Alex Jay, Braden Higgs, Ganessan Kichenadasse, Gillian Caughey, David Roder, Kerri Beckmann
We investigated the association between pre-existing comorbidities and prostate cancer management. High overall comorbidity burden, cardiac and respiratory disorders, thrombosis, diabetes, depression and anxiety, and chronic pain were associated with selecting EBRT, ADT alone or watchful waiting over RP.
-
Urological Cancers and ChatGPT: Comment Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Amnuay kleebayoon, Viroj Wiwanitkit
Abstract not available
-
-
Carboplatin in Metastatic Castrate Resistant Prostate Cancer: A Retrospective Study of Heavily Pretreated Patients (COMPACT) Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-22 Lara Pemberton, Connor Allen, Eleanor Handel, Andrew Weickhardt, Jeremy Shapiro, Ben Tran, Renea A. Taylor, Gail P. Risbridger, David W. Pook
Many clinicians consider carboplatin monotherapy in advanced castrate-resistant prostate cancer (CRPC) patients who have progressed through all available hormonal and standard chemotherapy treatment options, despite the limited evidence to justify its use. This retrospective analysis aimed to evaluate the use of carboplatin monotherapy in patients with refractory prostate cancer in Australia. Efficacy
-
Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-22 Hejia Yuan, Tianqi Wang, Peng Peng, Zhunan Xu, Fan Feng, Yuanshan Cui, Jian Ma, Jitao Wu
Urothelial bladder cancer (BCa) is a common malignant tumor of the urinary system. It has been identified that exosomal miRNAs contribute to the development of BCa. However, its significance and mechanism in the malignant biological behavior of BCa remain unclear. In this study, the influence of exosomal miRNAs on BCa progression was investigated. High-throughput sequencing was conducted to analyze
-
Incidental Coronary Arterial Calcification for Cardiovascular Risk Assessment in Men With Prostate Cancer Undergoing PET/CT Imaging Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-22 Preet A. Shaikh, Avira Som, Elena Deych, Alison J. Deng, Melissa A. Reimers, Brian C. Baumann, Eric H. Kim, Daniel J. Lenihan, Kathleen W. Zhang
Cardiovascular (CV) disease is common among men with prostate cancer and the leading cause of death in this population. There is a need for CV risk assessment tools that can be easily implemented in the prostate cancer treatment setting. Consecutive patients who underwent positron emission tomography/computed tomography (PET/CT) for recurrent prostate cancer at a single institution from 2012 to 2017
-
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-20 Daniel Boiarsky, Doga C. Gulhan, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, Rebecca Silver, Michelle S. Hirsch, Lynette M. Sholl, Atish D. Choudhury, Guruprasad Ananda, Peter J. Park, Alok K. Tewari, Jacob E. Berchuck
Immune checkpoint inhibitors (ICIs) have limited efficacy in prostate cancer (PCa). Better biomarkers are needed to predict responses to ICIs. We sought to demonstrate that a panel-based mutational signature identifies mismatch repair (MMR) deficient (MMRd) PCa and is a biomarker of response to pembrolizumab. Clinico-genomic data was obtained for 2664 patients with PCa sequenced at Dana-Farber Cancer
-
The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-17 Tatsushi Kawada, Takafumi Yanagisawa, Pawel Rajwa, Reza Sari Motlagh, Hadi Mostafaei, Fahad Quhal, Ekaterina Laukhtina, Maximilian Pallauf, Frederik König, Benjamin Pradere, Motoo Araki, Yasutomo Nasu, Shahrokh F. Shariat
We aimed to assess the prognostic value of tumor infiltrating lymphocytes (TILs) in patients with bladder cancer (BC) after radical cystectomy (RC). We searched Pubmed, Web of Science and Scopus in April 2022 to identify studies assessing the prognostic value of TILs, including a subset of lymphocytes (eg, CD3, CD8, FOXP3), after RC. The endpoints were overall survival and recurrent free survival.
-
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-15 Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
We aimed to clarify whether clinical outcomes following immune checkpoint inhibitor-based combination therapy differed according to the baseline kidney function of patients with advanced renal cell carcinoma. CKD did not affect the efficacy of IO-IO and IO-TKI regiments. In contrast, the risks of adverse events might be increased depending on the CKD severity, especially among those receiving IO-TKI
-
Surveillance or Dynamic Sentinel Lymph-Node Biopsy in Low-Risk Clinically N0 Penile Squamous Cell Carcinoma: Single-Institution Real World Data Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-15 Sebastiano Nazzani, Mario Catanzaro, Martina Bruniera, Tullio Torelli, Alberto Macchi, Silvia Stagni, Antonio Tesone, Carlo Silvani, Tommaso Ceccato, Valentina Bernasconi, Rodolfo Lanocita, Tommaso Cascella, Melanie Claps, Patrizia Giannatempo, Matteo Zimatore, Laura Cattaneo, Davide Biasoni, Emanuele Montanari, Nicola Nicolai
Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. We report on main oncological outcomes of a series of low-risk cN0 peSCC patients. Patients underwent primary tumor surgery and either observation or dynamic sentinel node biopsy. Observation is a safe and effective management for low-risk peSCC patients. Younger patients may be offered a mini-invasive
-
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-14 Martina Catalano, Ugo De Giorgi, Davide Bimbatti, Sebastiano Buti, Giuseppe Procopio, Pierangela Sepe, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello
In this retrospective study, among 107 mRCC patients with favorable risk receiving TKIs, those with 1 metastatic site had significantly longer overall survival and a trend of better progression-free survival compared to patients with > 1 site. Liver involvement was identified as independent poor prognostic factor for PFS. The site of metastases should be considered when choosing therapies for these
-
SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-12 Aimin Jiang, Ying Liu, Baohua Zhu, Yu Fang, Le Qu, Qiwei Yang, Peng Luo, Chen Cai, Linhui Wang
The emerging evidence suggested that senescence regulator genes were involved in multi cancers, which may be utilized as new targets for cancers. However, the dysregulation and clinical impact of senescence regulator genes in clear cell renal cell cancer (ccRCC) were still in foggy. Using multiomics data from TCGA-KIRC and other datasets, we comprehensively investigated the function of senescence regulator
-
Cystic Pelvic Masses in Men: A Presentation of Uncommon Cases and a Literature Review Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-11 Constantin Rieger, David Pfister, Lucas Kastner, Marie-Lisa Eich, Alexander Quaas, Yuri Tolkach, Axel Heidenreich
Unclear cystic masses in the pelvis in male patients are a rare situation and could be of benign or malignant origin. The underlying diseases demand for specific diagnostic and therapeutic approaches. We present a case series of 3 male patients with different clinical symptoms (perineal pain, urinary retention and a large scrotal cyst) related to cystic lesions in the pelvic region. On all patients
-
The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-10 Obaid Ur Rehman, Zain Ali Nadeem, Eeshal Fatima, Umar Akram, Hiba Imran, Ali Husnain, Arsalan Nadeem, Waqas Rasheed
Castration resistant prostate cancer (CRPC) is a challenging subset of prostate cancer associated with an extensive metastatic profile and high mortality. Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor and is employed as a second line treatment option for CRPC with an established efficacy profile in patients. The aim of this study is to assess the efficacy of
-
Bladder-Preserving Trimodality Therapy With Capecitabine Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-09 Connor Lynch, Randy F. Sweis, Parth Modi, Piyush K. Agarwal, Russell Z. Szmulewitz, Walter M. Stadler, Peter H. O'Donnell, Stanley L. Liauw, Sean P. Pitroda
While combined chemoradiotherapy is superior to radiotherapy alone bladder-preserving therapy in patients with bladder cancer, standard chemoradiotherapy regimens are prohibitively toxic for certain patients. We present results from our institutional experience treating patients with oral capecitabine concurrent with radiotherapy following transurethral resection of bladder tumor. Importantly, no patients
-
The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-09 Daeun Sung, Bogdana Schmidt, Jonathan David Tward
The International Staging Collaboration for Prostate Cancer (STAR-CAP) has been proposed as a risk model for prostate cancer with superior prognostic power compared to the current staging system. This study aimed to evaluate the performance of STAR-CAP in predicting the risk of subsequent therapy after initial treatment and the risk of developing metastases. The study included 3425 men from an institutional
-
Bladder Cancer and the Urinary Microbiome—New Insights and Future Directions: A Review Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-09 Angela E. Russo, Areeba Memon, Shahid Ahmed
The presence of a microbiome in the urinary system has been established through recent advancements in technology and investigation of microbial communities in the human body. The study of the taxonomic and genomic ecology of microbial communities has been greatly improved by the use of metagenomics. The research in this area has expanded our understanding of microbial ecosystems and shows that the
-
Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-06 Ziv Savin, Roy Mano, Alon Lazarovich, Barak Rosenzweig, Reut Shashar, Azik Hoffman, Ilona Pilosov, Yuval Freifeld, Sagi Arieh Shpitzer, Shay Golan, Ofer Yossepowitch, Mario Sofer
Symptomatic hydronephrosis associated with muscle invasive bladder cancer (MIBC) necessitates percutaneous nephrostomy (PCN) insertion before neoadjuvant chemotherapy (NAC). This study assesses the impact of PCN presence on standard intended NAC quality, its related complications and outcome after radical cystectomy (RC). The study comprises a retrospective, multicenter cohort of 193 consecutive RCs
-
Urological Cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-05 Faruk Ozgor, Ufuk Caglar, Ahmet Halis, Hakan Cakir, Ufuk Can Aksu, Ali Ayranci, Omer Sarilar
OpenAI has created ChatGPT, an artificial intelligence language model that has gained considerable recognition for its capacity to produce text responses resembling human language. Consequently, this study seeks to evaluate the effectiveness of ChatGPT's responses in addressing publicly accessible queries related to prostate, kidney, bladder, and testicular cancers. A comprehensive compilation of frequently
-
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-04 Mona Kafka, Giulia Giannini, Nastasiia Artamonova, Hannes Neuwirt, Heidemarie Ofner, Gero Kramer, Thomas Bauernhofer, Ferdinand Luger, Thomas Höfner, Wolfgang Loidl, Hubert Griessner, Lukas Lusuardi, Antonia Bergmaier, Andreas Berger, Thomas Winder, Sarah Weiss, Severin Bauinger, Steffen Krause, Martin Drerup, Elmar Heinrich, Magdalena Schneider, Stephan Madersbacher, Sonia Vallet, Franz Stoiber, Sarah
Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus changing treatment strategies in metastatic hormonesensitive prostate cancer (mHSPC). We conducted the first real-world analysis comprising 97 mHSPC patients from 16 Austrian medical
-
Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-03 Andrey Soares, Maria T. Bourlon, Alvin Wong, Amit Joshi, Denis Jardim, Ernesto Korbenfeld, Fadi El Karak, Francisco Orlandi, Henry Sze, Jawaher Ansari, Jose Zarba, Mubarak Al Mansour, Ray Manneh, Raja Thirumulai, Yu-Chieh Tsai, Waleed Al Morsi, Thomas Powles
Urothelial carcinoma (UC) is the 10 most common cancer globally with an almost 4 times higher prevalence in men. The main risk factors for development of urothelial carcinoma are advanced age, smoking, arsenic contamination, exposure to carcinogens. Metastatic urothelial carcinoma (mUC) has overall poor prognosis with a 5-year overall survival rate of only < 5%. The standard of care comprises of platinum-based
-
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-03 K. van der Zande, R.D. Tutuhatunewa-Louhanepessy, P. Hamberg, S. Ras, J.M. de Feijter, V.O. Dezentjé, A. Broeks, S. Cornelissen, A. Beeker, V. van der Noort, W. Zwart, A.M. Bergman
A proportion of mCRPC patients responds to carboplatin, however, predictive biomarkers are lacking. Forty-five mCRPC patients were treated with carboplatin and cabazitaxel following PSA progression on cabazitaxel monotherapy. A significant PSA response was observed in 26.6% of patients with limited adverse events, independent of clinical features or mutational profile. Addition of carboplatin to cabazitaxel
-
The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-27 Reha-Baris Incesu, Francesco Barletta, Cristina Cano Garcia, Lukas Scheipner, Simone Morra, Andrea Baudo, Anis Assad, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Luca Carmignani, Nicola Longo, Sascha Ahyai, Felix K.H. Chun, Alberto Briganti, Derya Tilki, Markus Graefen, Pierre I. Karakiewicz
The effect of treatment intensification (systemic therapy [ST] + cytoreductive nephrectomy (CN) vs. ST alone) is unknown regarding rates of other-cause mortality (OCM) in clear-cell metastatic renal cell carcinoma (ccmRCC). We hypothesized that intensified treatment (ST + CN) may result in higher OCM, than when ST is used alone. Within the Surveillance, Epidemiology, and End Results database, all ccmRCC
-
Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-25 Young-Gyu Park, Inkeun Park, Yongjae Kim, Ho-Su Lee, Woochang Lee, Shinkyo Yoon, Jae Lyun Lee
Metastatic disease affects approximately 15% to 17% of patients with pheochromocytomas and paragangliomas (PPGLs). Unfortunately, treatment options for metastatic PPGLs are limited and rely on small, nonrandomized clinical trials. The impact of germline mutation status on systemic treatment outcomes remains unclear. To address these gaps, we retrospectively evaluated treatment outcomes in patients
-
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-21 Francesco Ditonno, Alberto Bianchi, Sarah Malandra, Antonio Benito Porcaro, Emanuela Fantinel, Riccardo Negrelli, Matteo Ferro, Michele Milella, Matteo Brunelli, Riccardo Autorino, Maria Angela Cerruto, Alessandro Veccia, Alessandro Antonelli
Poly (ADP-ribose) polymerase inhibitors (PARPi) represent an option in selected cases of metastatic castration-resistant prostate cancer (mCRPC). The aim of the present systematic review and meta-analysis is to evaluate the efficacy and safety of approved (Olaparib, Rucaparib) and investigational (Talazoparib, Niraparib, Veliparib) PARPi in mCRPC patients. Three databases were queried for studies analyzing
-
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-21 Viktor Grünwald, James Larkin, Javier Puente, Jens Bedke, Camillo Porta
Renal cell carcinoma is the predominant histological type of kidney cancer with historically poor patient outcomes. Lenvatinib in combination with pembrolizumab is an approved first-line regimen for people with advanced renal cell carcinoma that showed clinically meaningful improvements in efficacy over sunitinib in the CLEAR trial; however, reduced patient exposure to treatment (often stemming from
-
Prognostic Significance of Lymph Node Density in Pathological Node Positive Urothelial Carcinoma of the Bladder -Upfront Surgery and Post Neoadjuvant Chemotherapy Cohorts Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-20 Ramamurthy Jaganmurugan, Amandeepsingh Arora, Udhay chandankhede, Gagan Prakash, Ganesh Bakshi, Amit Joshi, Santhosh Menon, Vedang Murthy, Mahendra Pal
To validate the role of lymph node density as a prognostic marker in patients undergoing primary surgery and postneoadjuvant therapy in pathological node-positive urothelial bladder carcinoma. Retrospective analysis of 503 patients who underwent radical cystectomy from 2006 to 2019 for muscle-invasive urothelial bladder carcinoma, of which 152 patients with pathological node-positive disease were analyzed
-
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-17 Chitra Priya Emperumal, Alessandro Villa, Caleb Hwang, David Oh, Lawrence Fong, Rahul Aggarwal, Bridget P. Keenan
Prostate Specific Membrane Antigen (PSMA)-targeted radionucleotide therapy has been shown to cause dry mouth, but the oral manifestations of PSMA-targeted immunotherapy have not been extensively studied. The aim of this study was to describe and quantify the oral manifestations of PSMA-targeted immunotherapies (bispecific antibodies or Chimeric Antigen Receptor T cell therapies) in the management of
-
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-15 Amanda Nizam, Ryan K. Rader, Alice Tzeng, Wei Wei, Iris Yeong-Fung Sheng, Allison Martin, Christopher E. Wee, Timothy D. Gilligan, Shilpa Gupta, Moshe C. Ornstein
As most patients with metastatic urothelial carcinoma (mUC) will be treated with immune checkpoint inhibitors (ICI), familiarity with their associated immune-related adverse events (irAEs) is critical. We describe the characteristics and outcomes of ICI-treated mUC patients who experienced irAEs requiring treatment interruption (TI) or permanent discontinuation. ICI-treated mUC patients who developed
-
Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-15 Geneviève Trépanier, Timo Nykopp, Raphaëlla Rosebush-Mercier, Typhaine Gris, Jonathan Fadel, Peter C. Black, Paul Toren
To predict recurrence and progression in non–muscle-invasive bladder cancer (NMIBC) patients receiving bacillus Calmette-Guérin (BCG), we evaluated circulating basophils as a biomarker that could be detected from the complete blood count. We use a pooled cohort of patients from the Centre Hospitalier Universitaire de Québec-Université Laval (2016-2020) and the Vancouver General Hospital (2010-2018)
-
First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2023-12-13 María Dolores Fenor de la Maza, Guillermo Villacampa, Bernardino Miñana, Guillermo Barbas Bernardos, Guillermo Andrés, Daniel Antonio González-Padilla, Fernando Ramón de Fata, Julián Sanz, Mauricio Cambeiro, Javier Aristu, Alfonso Gúrpide, Felipe Villacampa, Jose Luis Pérez Gracia
The standard of care for the first line management of metastatic urothelial carcinoma has been recently challenged, with the combination of pembrolizumab and enfortumab vedotin (P-EV) strongly arising as a practice-changing option from classical platinum-based chemotherapies. With this paradigm shift on the horizon new questions, including the most suitable second line of treatment for these patients